Additionally, inhibiting angiogenesis using antibodies targeting vascular endothelial growth factor or multi-tyrosine kinase receptor inhibitors can inhibit neoangiogenesis and induce the tumor vasculature normalization, activating the tumor-infiltrating lymphocytes’ infiltration into the TME.218 Numerous studies have revealed that modulating the T cell signaling pathway can help protect T lymphocytes from the immunosuppressive effects of TME. This evidence concerns the gene VEGFA and neoplasm.